Adult ; Aged ; Digoxin ; therapeutic use ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Heart Failure ; drug therapy ; Humans ; Male ; Middle Aged ; Phytotherapy

0.05). When MS and NID groups compared with NNID group, the difference was extremely significant(all P

ObjectiveTo imitate the process of identifying episode separations,which helps to improve the methodology of control episode separations.Methods Abstracts of inpatient record on all patients discharged from the hospitals in Beijing in 2010 were drawn from Beijing Public Health Information Center.Risk-adjusted by Diagnosis Related Groups-Beijing version (BJ-DRGs),two-weeks readmission rate was calculated at the whole city and hospital levels respectively.Comparing the readmission rate between these two levels,“suspicious objects”of episode separations can be found.In turn,the episode separations can be identified by detail analysis of these suspicious objects.Results In 2010,there were 13 DRGs with readmission rate exceeding 10％.Take the cases of dementia and other chronic brain disorders for example,the readmission rate for this type of inpatients in hospital G was much higher than the average level of the whole city.After the detail analysis of hospital G,the episode separations were found.Conclusion It is an effective method to indentify episode separations that calculating readmission rate based on the DRG risk-adjustment and using city level readmission rate as bench-mark.

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Chemotherapy, Adjuvant ; Genomics ; Humans ; Neoadjuvant Therapy ; Neoplasm Staging ; Proteomics ; Quality of Life ; Salvage Therapy ; Stomach Neoplasms ; drug therapy ; pathology ; surgery ; Survival Rate

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Colonic Neoplasms ; drug therapy ; pathology ; Disease Progression ; Drug Administration Schedule ; Guidelines as Topic ; Humans ; Neoplasm Staging ; Survival Analysis

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Chemotherapy, Adjuvant ; Chromosomal Instability ; Colonic Neoplasms ; drug therapy ; genetics ; pathology ; Deoxycytidine ; analogs & derivatives ; therapeutic use ; Fluorouracil ; administration & dosage ; analogs & derivatives ; therapeutic use ; Humans ; Leucovorin ; administration & dosage ; Microsatellite Instability ; Neoadjuvant Therapy ; Neoplasm Staging ; Organoplatinum Compounds ; administration & dosage ; Prognosis ; Rectal Neoplasms ; drug therapy ; genetics ; pathology ; Risk Factors

Amino Acid Metabolism, Inborn Errors ; Humans ; Infant, Newborn ; Isovaleryl-CoA Dehydrogenase ; deficiency ; Male ; Metabolism, Inborn Errors ; physiopathology

Antibodies, Monoclonal, Humanized ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bevacizumab ; Gastrointestinal Neoplasms ; classification ; epidemiology ; therapy ; Humans ; Indoles ; therapeutic use ; Neuroendocrine Tumors ; classification ; epidemiology ; therapy ; Octreotide ; therapeutic use ; Pancreatic Neoplasms ; classification ; epidemiology ; therapy ; Peptides, Cyclic ; therapeutic use ; Pyrroles ; therapeutic use ; Sirolimus ; analogs & derivatives ; therapeutic use ; Somatostatin ; analogs & derivatives ; therapeutic use

Antibodies, Monoclonal, Humanized ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Chemoradiotherapy ; Chemotherapy, Adjuvant ; Esophageal Neoplasms ; classification ; pathology ; surgery ; therapy ; Esophagogastric Junction ; Humans ; Stomach Neoplasms ; classification ; pathology ; surgery ; therapy ; Trastuzumab

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Chemotherapy, Adjuvant ; Colorectal Neoplasms ; radiotherapy ; surgery ; therapy ; Combined Modality Therapy ; Humans